S Squared Technology LLC Acquires Shares of 77,545 Krystal Biotech, Inc. $KRYS

Posted by Brian Himes on Aug 25th, 2026

S Squared Technology LLC bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 77,545 shares of the company’s stock, valued at approximately $28,821,150,000. Krystal Biotech makes up approximately 8.9% of S Squared Technology LLC’s investment portfolio, making the stock its 2nd largest position. S Squared Technology LLC owned 0.26% of Krystal Biotech at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. BlackRock Inc. bought a new position in Krystal Biotech in the 2nd quarter worth approximately $1,554,113,000. Avoro Capital Advisors LLC raised its holdings in Krystal Biotech by 4.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,888,888 shares of the company’s stock valued at $712,226,000 after acquiring an additional 111,111 shares during the period. State Street Corp lifted its position in shares of Krystal Biotech by 10.5% during the second quarter. State Street Corp now owns 1,355,346 shares of the company’s stock worth $186,306,000 after acquiring an additional 128,639 shares in the last quarter. Soleus Capital Management L.P. lifted its position in shares of Krystal Biotech by 108.9% during the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after acquiring an additional 481,200 shares in the last quarter. Finally, William Blair Investment Management LLC bought a new position in shares of Krystal Biotech in the second quarter worth $211,909,000. Institutional investors own 86.29% of the company’s stock.

Insiders Place Their Bets

In other news, EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the sale, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the transaction, the director directly owned 50,000 shares of the company’s stock, valued at $16,456,000. The trade was a 33.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 51,000 shares of company stock worth $16,278,020 in the last ninety days. 13.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on KRYS shares. Evercore reiterated an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 5th. Wall Street Zen downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Bank of America raised their target price on Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Citigroup upped their price target on Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Finally, TD Cowen upped their price target on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $365.40.

Get Our Latest Stock Analysis on KRYS

Krystal Biotech Price Performance

KRYS opened at $341.72 on Tuesday. The firm has a market capitalization of $10.11 billion, a P/E ratio of 42.82 and a beta of 0.53. Krystal Biotech, Inc. has a one year low of $136.73 and a one year high of $382.54. The company has a fifty day moving average price of $347.37 and a 200-day moving average price of $301.97.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. On average, analysts expect that Krystal Biotech, Inc. will post 7.68 earnings per share for the current year.

About Krystal Biotech

(Free Report)

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.